SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Brooklyn ImmunoTherapeutics, Inc. – ‘S-4’ on 10/2/20 – ‘EX-101.CAL’

On:  Friday, 10/2/20, at 6:11am ET   ·   Accession #:  1493152-20-18754   ·   File #:  333-249249

Previous ‘S-4’:  None   ·   Next:  ‘S-4/A’ on 11/25/20   ·   Latest:  ‘S-4/A’ on 1/20/21   ·   29 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/02/20  NTN Buzztime Inc.                 S-4                  177:18M                                    M2 Compliance LLC/FA

Registration Statement – Securities for a Merger   —   Form S-4   —   SA’33
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4         Registration Statement - Securities for a Merger    HTML   4.07M 
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML     52K 
 3: EX-23.4     Consent of Expert or Counsel                        HTML     48K 
 4: EX-23.5     Consent of Expert or Counsel                        HTML     48K 
 5: EX-99.3     Miscellaneous Exhibit                               HTML     50K 
12: R1          Document and Entity Information                     HTML     60K 
13: R2          Condensed Consolidated Balance Sheets               HTML    162K 
14: R3          Condensed Consolidated Balance Sheets               HTML     77K 
                (Parenthetical)                                                  
15: R4          Condensed Consolidated Statements of Operations     HTML    132K 
                and Comprehensive Loss                                           
16: R5          Condensed Consolidated Statements of Operations     HTML     50K 
                and Comprehensive Loss (Parenthetical)                           
17: R6          Condensed Consolidated Statements of Shareholders'  HTML    114K 
                Equity                                                           
18: R7          Condensed Consolidated Statements of Cash Flows     HTML    190K 
19: R8          Condensed Balance Sheets (Brooklyn                  HTML    138K 
                ImmunoTherapeutics, LLC)                                         
20: R9          Condensed Statements of Operations (Brooklyn        HTML     98K 
                ImmunoTherapeutics, LLC)                                         
21: R10         Condensed Statements of Changes in Members' Equity  HTML    143K 
                (Brooklyn ImmunoTherapeutics, LLC)                               
22: R11         Condensed Statements of Cash Flows (Brooklyn        HTML    257K 
                ImmunoTherapeutics, LLC)                                         
23: R12         Basis of Presentation                               HTML     56K 
24: R13         Organization of Company                             HTML     55K 
25: R14         Covid-19 Update                                     HTML     53K 
26: R15         Going Concern Uncertainty                           HTML     59K 
27: R16         Summary of Significant Accounting Policies And      HTML    125K 
                Estimates                                                        
28: R17         Restricted Cash                                     HTML     53K 
29: R18         Fixed Assets, Net                                   HTML     59K 
30: R19         Fair Value of Financial Instruments                 HTML     56K 
31: R20         Accrued Compensation                                HTML     55K 
32: R21         Concentrations of Risk                              HTML     54K 
33: R22         Revenue Recognition                                 HTML    104K 
34: R23         Basic and Diluted Earnings Per Common Share         HTML     53K 
35: R24         Shareholders' Equity                                HTML    104K 
36: R25         Income Taxes                                        HTML     81K 
37: R26         Debt                                                HTML     57K 
38: R27         Long-term Debt                                      HTML     54K 
39: R28         Leases                                              HTML    106K 
40: R29         Commitments and Contingencies                       HTML     52K 
41: R30         Disposition of Site Equipment to Be Installed and   HTML     55K 
                Fixed Assets                                                     
42: R31         Software Development Costs                          HTML     54K 
43: R32         Goodwill                                            HTML     60K 
44: R33         Accumulated Other Comprehensive Income              HTML     53K 
45: R34         Recent Accounting Pronouncements                    HTML     59K 
46: R35         Retirement Savings Plan                             HTML     51K 
47: R36         Subsequent Events                                   HTML     54K 
48: R37         Organization and Description of Business            HTML     59K 
                Operations (Brooklyn ImmunoTherapeutics, LLC)                    
49: R38         Description of Business (Brooklyn                   HTML     51K 
                ImmunoTherapeutics, LLC) (10-K)                                  
50: R39         Going Concern (Brooklyn ImmunoTherapeutics, LLC)    HTML     65K 
51: R40         Basis of Presentation and Summary of Significant    HTML     66K 
                Accounting Policies (Brooklyn ImmunoTherapeutics,                
                LLC)                                                             
52: R41         Summary of Significant Accounting Policies          HTML    144K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
53: R42         Fair Value of Financial Instruments (Brooklyn       HTML     67K 
                ImmunoTherapeutics, LLC)                                         
54: R43         Business Combination (Brooklyn ImmunoTherapeutics,  HTML     55K 
                LLC) (10-K)                                                      
55: R44         Property and Equipment (Brooklyn                    HTML     70K 
                ImmunoTherapeutics, LLC)                                         
56: R45         Goodwill and in Process Research and Development    HTML     50K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
57: R46         Security Deposits and Other Assets (Brooklyn        HTML     52K 
                ImmunoTherapeutics, LLC)                                         
58: R47         Accrued Expenses (Brooklyn ImmunoTherapeutics,      HTML     59K 
                LLC)                                                             
59: R48         Investor Deposits (Brooklyn ImmunoTherapeutics,     HTML     50K 
                LLC) (10-K)                                                      
60: R49         Loans Payable (Brooklyn ImmunoTherapeutics, LLC)    HTML     58K 
61: R50         Loans Payable and Loans Payable to Related Parties  HTML     53K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
62: R51         Commitments and Contingencies (Brooklyn             HTML     75K 
                ImmunoTherapeutics, LLC)                                         
63: R52         Stock-Based Compensation (Brooklyn                  HTML     56K 
                ImmunoTherapeutics, LLC)                                         
64: R53         Members' Equity (Brooklyn ImmunoTherapeutics, LLC)  HTML     52K 
65: R54         Stockholders' Deficiency and Members' Equity        HTML     69K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
66: R55         Income Tax (Brooklyn ImmunoTherapeutics, LLC)       HTML     95K 
                (10-K)                                                           
67: R56         Subsequent Events (Brooklyn ImmunoTherapeutics,     HTML     63K 
                LLC)                                                             
68: R57         Summary of Significant Accounting Policies And      HTML    174K 
                Estimates (Policies)                                             
69: R58         Basis of Presentation and Summary of Significant    HTML     90K 
                Accounting Policies (Policies) (Brooklyn                         
                ImmunoTherapeutics, LLC)                                         
70: R59         Summary of Significant Accounting Policies          HTML    123K 
                (Policies) (Brooklyn ImmunoTherapeutics, LLC)                    
                (10-K)                                                           
71: R60         Summary of Significant Accounting Policies And      HTML    110K 
                Estimates (Tables)                                               
72: R61         Fixed Assets, Net (Tables)                          HTML     60K 
73: R62         Accrued Compensation (Tables)                       HTML     53K 
74: R63         Revenue Recognition (Tables)                        HTML    110K 
75: R64         Shareholders' Equity (Tables)                       HTML     90K 
76: R65         Income Taxes (Tables)                               HTML     78K 
77: R66         Leases (Tables)                                     HTML     91K 
78: R67         Goodwill (Tables)                                   HTML     57K 
79: R68         Business Combination (Tables) (Brooklyn             HTML     54K 
                ImmunoTherapeutics, LLC) (10-K)                                  
80: R69         Fair Value of Financial Instruments (Tables)        HTML     57K 
                (Brooklyn ImmunoTherapeutics, LLC)                               
81: R70         Property and Equipment (Tables) (Brooklyn           HTML     64K 
                ImmunoTherapeutics, LLC)                                         
82: R71         Accrued Expenses (Tables) (Brooklyn                 HTML     58K 
                ImmunoTherapeutics, LLC)                                         
83: R72         Commitments and Contingencies (Tables) (Brooklyn    HTML     53K 
                ImmunoTherapeutics, LLC) (10-K)                                  
84: R73         Stockholders' Deficiency and Members' Equity        HTML     77K 
                (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)               
85: R74         Income Tax (Tables) (Brooklyn ImmunoTherapeutics,   HTML     83K 
                LLC) (10-K)                                                      
86: R75         Basis of Presentation (Details Narrative)           HTML     49K 
87: R76         Organization of Company (Details Narrative) (10-K)  HTML     55K 
88: R77         Covid-19 Update (Details Narrative)                 HTML     54K 
89: R78         Going Concern Uncertainty (Details Narrative)       HTML     65K 
90: R79         Going Concern Uncertainty (Details Narrative)       HTML     72K 
                (10-K)                                                           
91: R80         Summary of Significant Accounting Policies and      HTML    193K 
                Estimates (Details Narrative) (10-K)                             
92: R81         Summary of Significant Accounting Policies and      HTML     72K 
                Estimates - Schedule of Disaggregation of Revenues               
                (Details) (10-K)                                                 
93: R82         Summary of Significant Accounting Policies and      HTML     55K 
                Estimates - Schedule of Revenues Geographic                      
                Breakdown (Details) (10-K)                                       
94: R83         Summary of Significant Accounting Policies and      HTML     59K 
                Estimates - Schedule of Contract Liabilities                     
                (Details) (10-K)                                                 
95: R84         Summary of Significant Accounting Policies and      HTML     57K 
                Estimates - Schedule of Unamortized Installation                 
                Cost and Sales Commissions (Details) (10-K)                      
96: R85         Restricted Cash (Details Narrative)                 HTML     66K 
97: R86         Restricted Cash (Details Narrative) (10-K)          HTML     69K 
98: R87         Fixed Assets, Net (Details Narrative) (10-K)        HTML     50K 
99: R88         Fixed Assets, Net - Schedule of Property and        HTML     64K 
                Equipment (Details) (10-K)                                       
100: R89         Fixed Assets, Net - Schedule of Asset Geographic    HTML     53K  
                Breakdown (Details) (10-K)                                       
101: R90         Accrued Compensation - Schedule of Accrued          HTML     60K  
                Compensation (Details) (10-K)                                    
102: R91         Concentrations of Risk (Details Narrative) (10-K)   HTML     69K  
103: R92         Revenue Recognition - (Details Narrative)           HTML     56K  
104: R93         Revenue Recognition - Schedule of Disaggregates     HTML     72K  
                Material Revenue (Details)                                       
105: R94         Revenue Recognition - Schedule of Revenues          HTML     56K  
                Geographic Breakdown (Details)                                   
106: R95         Revenue Recognition - Schedule of Contract          HTML     60K  
                Liabilities (Details)                                            
107: R96         Revenue Recognition - Schedule of Unamortized       HTML     58K  
                Installation Cost and Sales Commissions (Details)                
108: R97         Basic and Diluted Earnings Per Common Share         HTML     51K  
                (Details Narrative)                                              
109: R98         Basic and Diluted Earnings Per Common Share         HTML     51K  
                (Details Narrative) (10-K)                                       
110: R99         Shareholders' Equity (Details Narrative)            HTML     85K  
111: R100        Shareholders' Equity (Details Narrative) (10-K)     HTML    160K  
112: R101        Shareholders' Equity - Schedule of Restricted       HTML     52K  
                Stock and Common Stock Unit Vested (Details)                     
113: R102        Shareholders' Equity - Schedule of Weighted         HTML     58K  
                Average Assumptions (Details) (10-K)                             
114: R103        Shareholders' Equity - Summary of Stock Option      HTML     98K  
                Activity (Details) (10-K)                                        
115: R104        Shareholders' Equity - Summary of Restricted Stock  HTML     70K  
                Unit Activity (Details) (10-K)                                   
116: R105        Shareholders' Equity - Summary of Warrant           HTML     71K  
                Activities (Details) (10-K)                                      
117: R106        Income Taxes (Details Narrative) (10-K)             HTML     65K  
118: R107        Income Taxes - Schedule of Current and Deferred     HTML     84K  
                Income Tax Provision (Benefit) (Details) (10-K)                  
119: R108        Income Taxes - Schedule of Deferred Tax Assets and  HTML     89K  
                Liabilities (Details) (10-K)                                     
120: R109        Income Taxes - Schedule of Reconciliation of        HTML     66K  
                Expected Income Taxes (Details) (10-K)                           
121: R110        Debt (Details Narrative)                            HTML    125K  
122: R111        Long-term Debt (Details Narrative) (10-K)           HTML     82K  
123: R112        Leases (Details Narrative)                          HTML    106K  
124: R113        Leases (Details Narrative) (10-K)                   HTML     72K  
125: R114        Leases - Schedule of Operating Lease Right-of-use   HTML     73K  
                Assets and Liabilities (Details)                                 
126: R115        Leases - Schedule of Operating Lease Right-of-use   HTML     68K  
                Assets and Liabilities (Details) (10-K)                          
127: R116        Leases - Schedule of Maturities of Operating        HTML     63K  
                Leases (Details)                                                 
128: R117        Leases - Schedule of Maturities of Operating        HTML     68K  
                Leases (Details) (10-K)                                          
129: R118        Leases - Schedule of Financing Lease Right-of-use   HTML     62K  
                Assets and Liabilities (Details)                                 
130: R119        Leases - Schedule of Financing Lease Right-of-use   HTML     60K  
                Assets and Liabilities (Details) (10-K)                          
131: R120        Leases - Schedule of Maturities of Financing        HTML     59K  
                Leases (Details)                                                 
132: R121        Leases - Schedule of Maturities of Financing        HTML     59K  
                Leases (Details) (10-K)                                          
133: R122        Disposition of Site Equipment to Be Installed and   HTML     69K  
                Fixed Assets (Details Narrative)                                 
134: R123        Software Development Costs (Details Narrative)      HTML     56K  
135: R124        Goodwill (Details Narrative)                        HTML     54K  
136: R125        Goodwill (Details Narrative) (10-K)                 HTML     54K  
137: R126        Goodwill - Schedule of Goodwill (Details)           HTML     57K  
138: R127        Goodwill - Schedule of Goodwill (Details) (10-K)    HTML     59K  
139: R128        Accumulated Other Comprehensive Income (Details     HTML     51K  
                Narrative)                                                       
140: R129        Accumulated Other Comprehensive Income (Details     HTML     51K  
                Narrative) (10-K)                                                
141: R130        Retirement Savings Plan (Details Narrative) (10-K)  HTML     51K  
142: R131        Subsequent Events (Details Narrative) (10-K)        HTML    116K  
143: R132        Going Conern (Details Narrative) (Brooklyn          HTML     63K  
                ImmunoTherapeutics, LLC)                                         
144: R133        Basis of Presentation and Summary of Significant    HTML     56K  
                Accounting Policies (Details Narrative) (Brooklyn                
                ImmunoTherapeutics, LLC)                                         
145: R134        Fair Value of Financial Instruments - Schedule of   HTML     58K  
                Fair Value of Liabilities (Details) (Brooklyn                    
                ImmunoTherapeutics, LLC)                                         
146: R135        Property and Equipment (Details Narrative)          HTML     51K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
147: R136        Property and Equipment - Schedule of Property and   HTML     62K  
                Equipment (Details) (Brooklyn ImmunoTherapeutics,                
                LLC)                                                             
148: R137        Security Deposits and Other Assets (Details         HTML     59K  
                Narrative) (Brooklyn ImmunoTherapeutics, LLC)                    
149: R138        Accrued Expenses (Details) (Brooklyn                HTML     61K  
                ImmunoTherapeutics, LLC)                                         
150: R139        Loans Payable (Details Narrative) (Brooklyn         HTML     53K  
                ImmunoTherapeutics, LLC)                                         
151: R140        Commitments and Contingencies (Details Narrative)   HTML     82K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
152: R141        Stock-Based Compensation (Details Narrative)        HTML     51K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
153: R142        Members' Equity (Details Narrative) (Brooklyn       HTML     61K  
                ImmunoTherapeutics, LLC)                                         
154: R143        Subsequent Events (Details Narrative) (Brooklyn     HTML     77K  
                ImmunoTherapeutics, LLC)                                         
155: R144        Going Conern (Details Narrative) (Brooklyn          HTML     81K  
                ImmunoTherapeutics, LLC) (10-K)                                  
156: R145        Summary of Significant Accounting Policies          HTML     66K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
157: R146        Business Combination (Details Narrative) (Brooklyn  HTML     58K  
                ImmunoTherapeutics, LLC) (10-K)                                  
158: R147        Business Combination - Schedule of Purchase Price   HTML     77K  
                for Acquisition (Details) (Brooklyn                              
                ImmunoTherapeutics, LLC) (10-K)                                  
159: R148        Property and Equipment (Details Narative)           HTML     57K  
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
160: R149        Property and Equipment - Schedule of Property and   HTML     62K  
                Equipment (Details) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
161: R150        Goodwill and in Process Research and Development    HTML     53K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
162: R151        Security Deposits and Other Assets (Details         HTML     59K  
                Narrative) (Brooklyn ImmunoTherapeutics, LLC)                    
                (10-K)                                                           
163: R152        Accrued Expenses (Details) (Brooklyn                HTML     64K  
                ImmunoTherapeutics, LLC) (10K)                                   
164: R153        Investor Deposits (Details Narrative) (Brooklyn     HTML     49K  
                ImmunoTherapeutics, LLC) (10-K)                                  
165: R154        Loans Payable and Loans Payable to Related Parties  HTML     96K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
166: R155        Commitments and Contingencies (Details Narrative)   HTML    121K  
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
167: R156        Commitments and Contingencies - Schedule of Future  HTML     67K  
                Commitments of Operating Lease (Details) (Brooklyn               
                ImmunoTherapeutics, LLC)                                         
168: R157        Stockholders' Deficiency and Members' Equity        HTML    161K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
169: R158        Stockholders' Deficiency and Members' Equity -      HTML     86K  
                Schedule of Stock Option Activity (Details)                      
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
170: R159        Stockholders' Deficiency and Members' Equity -      HTML     65K  
                Schedule of Stock Options Outstanding and                        
                Exercisable (Details) (Brooklyn                                  
                ImmunoTherapeutics, LLC) (10-K)                                  
171: R160        Income Tax (Details Narrative) (Brooklyn            HTML     55K  
                ImmunoTherapeutics, LLC) (10-K)                                  
172: R161        Income Tax - Schedule of Income Tax Benefit         HTML     79K  
                (Details) (Brooklyn ImmunoTherapeutics, LLC)                     
                (10-K)                                                           
173: R162        Income Tax - Schedule of Deferred Tax Assets and    HTML     55K  
                Liabilities (Details) (Brooklyn                                  
                ImmunoTherapeutics, LLC) (10-K)                                  
174: R163        Subsequent Events (Details Narrative) (Brooklyn     HTML     55K  
                ImmunoTherapeutics, LLC) (10-K)                                  
176: XML         IDEA XML File -- Filing Summary                      XML    356K  
175: EXCEL       IDEA Workbook of Financial Reports                  XLSX    272K  
 6: EX-101.INS  XBRL Instance -- ntn-20200630                        XML   3.37M 
 8: EX-101.CAL  XBRL Calculations -- ntn-20200630_cal                XML    454K 
 9: EX-101.DEF  XBRL Definitions -- ntn-20200630_def                 XML   1.92M 
10: EX-101.LAB  XBRL Labels -- ntn-20200630_lab                      XML   2.05M 
11: EX-101.PRE  XBRL Presentations -- ntn-20200630_pre               XML   2.24M 
 7: EX-101.SCH  XBRL Schema -- ntn-20200630                          XSD    441K 
177: ZIP         XBRL Zipped Folder -- 0001493152-20-018754-xbrl      Zip    323K

‘EX-101.CAL’   —   XBRL Calculations — ntn-20200630_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" standalone="no" encoding="windows-1252"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5a -->
<!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
<!-- Field: Doc-Info; Name: Source; Value: NTN%2D20200630 S%2D4 DFN.xfr; Date: 2020%2D10%2D02T04:37:02Z -->
<!-- Field: Doc-Info; Name: Status; Value: 0x82920001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://buzztime.com/role/DocumentAndEntityInformation" xlink:href="ntn-20200630.xsd#DocumentAndEntityInformation" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BalanceSheets" xlink:href="ntn-20200630.xsd#BalanceSheets" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BalanceSheetsParenthetical" xlink:href="ntn-20200630.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="ntn-20200630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="ntn-20200630.xsd#StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StatementsOfShareholdersEquity" xlink:href="ntn-20200630.xsd#StatementsOfShareholdersEquity" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StatementsOfCashFlows" xlink:href="ntn-20200630.xsd#StatementsOfCashFlows" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BalanceSheetsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#BalanceSheetsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StatementsOfOperationsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#StatementsOfOperationsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StatementsOfChangesInMembersEquityBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#StatementsOfChangesInMembersEquityBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StatementsOfCashFlowsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#StatementsOfCashFlowsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentation" xlink:href="ntn-20200630.xsd#BasisOfPresentation" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/OrganizationOfCompany" xlink:href="ntn-20200630.xsd#OrganizationOfCompany" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Covid-19Update" xlink:href="ntn-20200630.xsd#Covid-19Update" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoingConcernUncertainty" xlink:href="ntn-20200630.xsd#GoingConcernUncertainty" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RestrictedCash" xlink:href="ntn-20200630.xsd#RestrictedCash" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNet" xlink:href="ntn-20200630.xsd#FixedAssetsNet" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/FairValueOfFinancialInstruments" xlink:href="ntn-20200630.xsd#FairValueOfFinancialInstruments" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccruedCompensation" xlink:href="ntn-20200630.xsd#AccruedCompensation" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ConcentrationsOfRisk" xlink:href="ntn-20200630.xsd#ConcentrationsOfRisk" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition" xlink:href="ntn-20200630.xsd#RevenueRecognition" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BasicAndDilutedEarningsPerCommonShare" xlink:href="ntn-20200630.xsd#BasicAndDilutedEarningsPerCommonShare" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity" xlink:href="ntn-20200630.xsd#ShareholdersEquity" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxes" xlink:href="ntn-20200630.xsd#IncomeTaxes" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Debt" xlink:href="ntn-20200630.xsd#Debt" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Long-termDebt" xlink:href="ntn-20200630.xsd#Long-termDebt" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Leases" xlink:href="ntn-20200630.xsd#Leases" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingencies" xlink:href="ntn-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/DispositionOfSiteEquipmentToBeInstalledAndFixedAssets" xlink:href="ntn-20200630.xsd#DispositionOfSiteEquipmentToBeInstalledAndFixedAssets" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SoftwareDevelopmentCosts" xlink:href="ntn-20200630.xsd#SoftwareDevelopmentCosts" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Goodwill" xlink:href="ntn-20200630.xsd#Goodwill" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccumulatedOtherComprehensiveIncome" xlink:href="ntn-20200630.xsd#AccumulatedOtherComprehensiveIncome" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RecentAccountingPronouncements" xlink:href="ntn-20200630.xsd#RecentAccountingPronouncements" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RetirementSavingsPlan" xlink:href="ntn-20200630.xsd#RetirementSavingsPlan" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SubsequentEvents" xlink:href="ntn-20200630.xsd#SubsequentEvents" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/OrganizationAndDescriptionOfBusinessOperationsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#OrganizationAndDescriptionOfBusinessOperationsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/DescriptionOfBusinessBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#DescriptionOfBusinessBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoingConcernBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#GoingConcernBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/FairValueOfFinancialInstrumentsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#FairValueOfFinancialInstrumentsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BusinessCombinationBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#BusinessCombinationBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipmentBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#PropertyAndEquipmentBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoodwillAndInProcessResearchAndDevelopmentBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#GoodwillAndInProcessResearchAndDevelopmentBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SecurityDepositsAndOtherAssetsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#SecurityDepositsAndOtherAssetsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccruedExpensesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#AccruedExpensesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/InvestorDepositsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#InvestorDepositsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/LoansPayableBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#LoansPayableBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/LoansPayableAndLoansPayableToRelatedPartiesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#LoansPayableAndLoansPayableToRelatedPartiesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingenciesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#CommitmentsAndContingenciesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Stock-basedCompensationBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#Stock-basedCompensationBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/MembersEquityBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#MembersEquityBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquityBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#StockholdersDeficiencyAndMembersEquityBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#IncomeTaxBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SubsequentEventsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#SubsequentEventsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNetTables" xlink:href="ntn-20200630.xsd#FixedAssetsNetTables" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccruedCompensationTables" xlink:href="ntn-20200630.xsd#AccruedCompensationTables" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognitionTables" xlink:href="ntn-20200630.xsd#RevenueRecognitionTables" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquityTables" xlink:href="ntn-20200630.xsd#ShareholdersEquityTables" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxesTables" xlink:href="ntn-20200630.xsd#IncomeTaxesTables" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/LeasesTables" xlink:href="ntn-20200630.xsd#LeasesTables" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoodwillTables" xlink:href="ntn-20200630.xsd#GoodwillTables" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BusinessCombinationTablesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#BusinessCombinationTablesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/FairValueOfFinancialInstrumentsTablesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#FairValueOfFinancialInstrumentsTablesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipmentTablesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#PropertyAndEquipmentTablesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccruedExpensesTablesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#AccruedExpensesTablesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingenciesTablesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#CommitmentsAndContingenciesTablesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquityTablesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#StockholdersDeficiencyAndMembersEquityTablesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxTablesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#IncomeTaxTablesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ntn-20200630.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/OrganizationOfCompanyDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#OrganizationOfCompanyDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Covid-19UpdateDetailsNarrative" xlink:href="ntn-20200630.xsd#Covid-19UpdateDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoingConcernUncertaintyDetailsNarrative" xlink:href="ntn-20200630.xsd#GoingConcernUncertaintyDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoingConcernUncertaintyDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#GoingConcernUncertaintyDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfDisaggregationOfRevenuesDetails10-k" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfDisaggregationOfRevenuesDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfRevenuesGeographicBreakdownDetails10-k" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfRevenuesGeographicBreakdownDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfContractLiabilitiesDetails10-k" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfContractLiabilitiesDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails10-k" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RestrictedCashDetailsNarrative" xlink:href="ntn-20200630.xsd#RestrictedCashDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RestrictedCashDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#RestrictedCashDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNetDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#FixedAssetsNetDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNet-ScheduleOfPropertyAndEquipmentDetails10-k" xlink:href="ntn-20200630.xsd#FixedAssetsNet-ScheduleOfPropertyAndEquipmentDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNet-ScheduleOfAssetGeographicBreakdownDetails10-k" xlink:href="ntn-20200630.xsd#FixedAssetsNet-ScheduleOfAssetGeographicBreakdownDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccruedCompensation-ScheduleOfAccruedCompensationDetails10-k" xlink:href="ntn-20200630.xsd#AccruedCompensation-ScheduleOfAccruedCompensationDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ConcentrationsOfRiskDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#ConcentrationsOfRiskDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-DetailsNarrative" xlink:href="ntn-20200630.xsd#RevenueRecognition-DetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-ScheduleOfDisaggregatesMaterialRevenueDetails" xlink:href="ntn-20200630.xsd#RevenueRecognition-ScheduleOfDisaggregatesMaterialRevenueDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-ScheduleOfRevenuesGeographicBreakdownDetails" xlink:href="ntn-20200630.xsd#RevenueRecognition-ScheduleOfRevenuesGeographicBreakdownDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-ScheduleOfContractLiabilitiesDetails" xlink:href="ntn-20200630.xsd#RevenueRecognition-ScheduleOfContractLiabilitiesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails" xlink:href="ntn-20200630.xsd#RevenueRecognition-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BasicAndDilutedEarningsPerCommonShareDetailsNarrative" xlink:href="ntn-20200630.xsd#BasicAndDilutedEarningsPerCommonShareDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BasicAndDilutedEarningsPerCommonShareDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#BasicAndDilutedEarningsPerCommonShareDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquityDetailsNarrative" xlink:href="ntn-20200630.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquityDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#ShareholdersEquityDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-ScheduleOfRestrictedStockAndCommonStockUnitVestedDetails" xlink:href="ntn-20200630.xsd#ShareholdersEquity-ScheduleOfRestrictedStockAndCommonStockUnitVestedDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-ScheduleOfWeightedAverageAssumptionsDetails10-k" xlink:href="ntn-20200630.xsd#ShareholdersEquity-ScheduleOfWeightedAverageAssumptionsDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-SummaryOfStockOptionActivityDetails10-k" xlink:href="ntn-20200630.xsd#ShareholdersEquity-SummaryOfStockOptionActivityDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-SummaryOfRestrictedStockUnitActivityDetails10-k" xlink:href="ntn-20200630.xsd#ShareholdersEquity-SummaryOfRestrictedStockUnitActivityDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-SummaryOfWarrantActivitiesDetails10-k" xlink:href="ntn-20200630.xsd#ShareholdersEquity-SummaryOfWarrantActivitiesDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxesDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#IncomeTaxesDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxes-ScheduleOfCurrentAndDeferredIncomeTaxProvisionBenefitDetails10-k" xlink:href="ntn-20200630.xsd#IncomeTaxes-ScheduleOfCurrentAndDeferredIncomeTaxProvisionBenefitDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:href="ntn-20200630.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxes-ScheduleOfReconciliationOfExpectedIncomeTaxesDetails10-k" xlink:href="ntn-20200630.xsd#IncomeTaxes-ScheduleOfReconciliationOfExpectedIncomeTaxesDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/DebtDetailsNarrative" xlink:href="ntn-20200630.xsd#DebtDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Long-termDebtDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#Long-termDebtDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/LeasesDetailsNarrative" xlink:href="ntn-20200630.xsd#LeasesDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/LeasesDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#LeasesDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:href="ntn-20200630.xsd#Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:href="ntn-20200630.xsd#Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfOperatingLeasesDetails" xlink:href="ntn-20200630.xsd#Leases-ScheduleOfMaturitiesOfOperatingLeasesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfOperatingLeasesDetails10-k" xlink:href="ntn-20200630.xsd#Leases-ScheduleOfMaturitiesOfOperatingLeasesDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:href="ntn-20200630.xsd#Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:href="ntn-20200630.xsd#Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails" xlink:href="ntn-20200630.xsd#Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails10-k" xlink:href="ntn-20200630.xsd#Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/DispositionOfSiteEquipmentToBeInstalledAndFixedAssetsDetailsNarrative" xlink:href="ntn-20200630.xsd#DispositionOfSiteEquipmentToBeInstalledAndFixedAssetsDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SoftwareDevelopmentCostsDetailsNarrative" xlink:href="ntn-20200630.xsd#SoftwareDevelopmentCostsDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoodwillDetailsNarrative" xlink:href="ntn-20200630.xsd#GoodwillDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoodwillDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#GoodwillDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Goodwill-ScheduleOfGoodwillDetails" xlink:href="ntn-20200630.xsd#Goodwill-ScheduleOfGoodwillDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Goodwill-ScheduleOfGoodwillDetails10-k" xlink:href="ntn-20200630.xsd#Goodwill-ScheduleOfGoodwillDetails10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccumulatedOtherComprehensiveIncomeDetailsNarrative" xlink:href="ntn-20200630.xsd#AccumulatedOtherComprehensiveIncomeDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccumulatedOtherComprehensiveIncomeDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#AccumulatedOtherComprehensiveIncomeDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/RetirementSavingsPlanDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#RetirementSavingsPlanDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SubsequentEventsDetailsNarrative10-k" xlink:href="ntn-20200630.xsd#SubsequentEventsDetailsNarrative10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/FairValueOfFinancialInstruments-ScheduleOfFairValueOfLiabilitiesDetailsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#FairValueOfFinancialInstruments-ScheduleOfFairValueOfLiabilitiesDetailsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipmentDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#PropertyAndEquipmentDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/LoansPayableDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#LoansPayableDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/Stock-basedCompensationDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#Stock-basedCompensationDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/MembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#MembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SubsequentEventsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#SubsequentEventsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BusinessCombinationDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#BusinessCombinationDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/BusinessCombination-ScheduleOfPurchasePriceForAcquisitionDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#BusinessCombination-ScheduleOfPurchasePriceForAcquisitionDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipmentDetailsNarativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#PropertyAndEquipmentDetailsNarativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/GoodwillAndInProcessResearchAndDevelopmentDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#GoodwillAndInProcessResearchAndDevelopmentDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc10k" xlink:href="ntn-20200630.xsd#AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc10k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/InvestorDepositsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#InvestorDepositsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/LoansPayableAndLoansPayableToRelatedPartiesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#LoansPayableAndLoansPayableToRelatedPartiesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingencies-ScheduleOfFutureCommitmentsOfOperatingLeaseDetailsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200630.xsd#CommitmentsAndContingencies-ScheduleOfFutureCommitmentsOfOperatingLeaseDetailsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#StockholdersDeficiencyAndMembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionActivityDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionActivityDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionsOutstandingAndExercisableDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionsOutstandingAndExercisableDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#IncomeTaxDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTax-ScheduleOfIncomeTaxBenefitDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#IncomeTax-ScheduleOfIncomeTaxBenefitDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/IncomeTax-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#IncomeTax-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:roleRef roleURI="http://buzztime.com/role/SubsequentEventsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200630.xsd#SubsequentEventsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_SiteEquipmentToBeInstalled" xlink:label="loc_NTNSiteEquipmentToBeInstalled"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_NTNSiteEquipmentToBeInstalled" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaapCapitalizedComputerSoftwareNet"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCapitalizedComputerSoftwareNet" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent"/>
<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaapSalesAndExciseTaxPayableCurrent"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapSalesAndExciseTaxPayableCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent"/>
<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent"/>
<link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent"/>
<link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaapDeferredRentCredit"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRentCredit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DirectOperatingCosts" xlink:label="loc_us-gaapDirectOperatingCosts"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDirectOperatingCosts" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareImpairments1" xlink:label="loc_us-gaapCapitalizedComputerSoftwareImpairments1"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapCapitalizedComputerSoftwareImpairments1" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_GainOnAssetSale" xlink:label="loc_NTNGainOnAssetSale"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NTNGainOnAssetSale" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="loc_us-gaapGainLossOnTerminationOfLease"/>
<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnTerminationOfLease" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_LossFromDispositionOfAssets" xlink:label="loc_NTNLossFromDispositionOfAssets"/>
<link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NTNLossFromDispositionOfAssets" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareImpairments1" xlink:label="loc_us-gaapCapitalizedComputerSoftwareImpairments1"/>
<link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapCapitalizedComputerSoftwareImpairments1" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss"/>
<link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts"/>
<link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable"/>
<link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_IncreaseDecreaseSiteEquipmentToBeInstalled" xlink:label="loc_NTNIncreaseDecreaseSiteEquipmentToBeInstalled"/>
<link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NTNIncreaseDecreaseSiteEquipmentToBeInstalled" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_IncreaseDecreaseOperatingLeaseLiabilities" xlink:label="loc_NTNIncreaseDecreaseOperatingLeaseLiabilities"/>
<link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NTNIncreaseDecreaseOperatingLeaseLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable"/>
<link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities"/>
<link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability"/>
<link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities"/>
<link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_TransferOfFixedAssetsToSalestypeLease" xlink:label="loc_NTNTransferOfFixedAssetsToSalestypeLease"/>
<link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NTNTransferOfFixedAssetsToSalestypeLease" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities"/>
<link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCapitalImprovements" xlink:label="loc_us-gaapPaymentsForCapitalImprovements"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForCapitalImprovements" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering"/>
<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_TaxWithholdingPaymentsForNetShareSettlementOfVestedRestrictedStockUnits" xlink:label="loc_NTNTaxWithholdingPaymentsForNetShareSettlementOfVestedRestrictedStockUnits"/>
<link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_NTNTaxWithholdingPaymentsForNetShareSettlementOfVestedRestrictedStockUnits" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_DividendsPaidToSeriesPreferredShareholders" xlink:label="loc_NTNDividendsPaidToSeriesPreferredShareholders"/>
<link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_NTNDividendsPaidToSeriesPreferredShareholders" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BalanceSheetsBrooklynImmunotherapeuticsLlc" xlink:title="00000008 - Statement - Condensed Balance Sheets (Brooklyn ImmunoTherapeutics, LLC)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_InProcessResearchAndDevelopment" xlink:label="loc_NTNInProcessResearchAndDevelopment"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_NTNInProcessResearchAndDevelopment" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_AccruedExpensesCurrent" xlink:label="loc_NTNAccruedExpensesCurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_NTNAccruedExpensesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_InvestorDeposits" xlink:label="loc_NTNInvestorDeposits"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_NTNInvestorDeposits" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_PaycheckProtectionProgramLoan" xlink:label="loc_NTNPaycheckProtectionProgramLoan"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_NTNPaycheckProtectionProgramLoan" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfOperationsBrooklynImmunotherapeuticsLlc" xlink:title="00000009 - Statement - Condensed Statements of Operations (Brooklyn ImmunoTherapeutics, LLC)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_InterestExpenses" xlink:label="loc_NTNInterestExpenses"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_NTNInterestExpenses" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfChangesInMembersEquityBrooklynImmunotherapeuticsLlc" xlink:title="00000010 - Statement - Condensed Statements of Changes in Members&apos; Equity (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfCashFlowsBrooklynImmunotherapeuticsLlc" xlink:title="00000011 - Statement - Condensed Statements of Cash Flows (Brooklyn ImmunoTherapeutics, LLC)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_LossOnOperatingSublease" xlink:label="loc_NTNLossOnOperatingSublease"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_NTNLossOnOperatingSublease" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInSecurityDeposits"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInSecurityDeposits" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_IncreaseDecreaseInLeaseLiability" xlink:label="loc_NTNIncreaseDecreaseInLeaseLiability"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_NTNIncreaseDecreaseInLeaseLiability" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities"/>
<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_PaymentsToPatentCosts" xlink:label="loc_NTNPaymentsToPatentCosts"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_NTNPaymentsToPatentCosts" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:label="loc_us-gaapCashAcquiredInExcessOfPaymentsToAcquireBusiness"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapCashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_ProceedsFromInvestorDeposits" xlink:label="loc_NTNProceedsFromInvestorDeposits"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_NTNProceedsFromInvestorDeposits" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_ProceedsFromCollectionOfSubscriptionsReceivable" xlink:label="loc_NTNProceedsFromCollectionOfSubscriptionsReceivable"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_NTNProceedsFromCollectionOfSubscriptionsReceivable" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BasisOfPresentation" xlink:title="00000012 - Disclosure - Basis of Presentation"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/OrganizationOfCompany" xlink:title="00000013 - Disclosure - Organization of Company"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Covid-19Update" xlink:title="00000014 - Disclosure - Covid-19 Update"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoingConcernUncertainty" xlink:title="00000015 - Disclosure - Going Concern Uncertainty"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000016 - Disclosure - Summary of Significant Accounting Policies And Estimates"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RestrictedCash" xlink:title="00000017 - Disclosure - Restricted Cash"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/FixedAssetsNet" xlink:title="00000018 - Disclosure - Fixed Assets, Net"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/FairValueOfFinancialInstruments" xlink:title="00000019 - Disclosure - Fair Value of Financial Instruments"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccruedCompensation" xlink:title="00000020 - Disclosure - Accrued Compensation"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ConcentrationsOfRisk" xlink:title="00000021 - Disclosure - Concentrations of Risk"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RevenueRecognition" xlink:title="00000022 - Disclosure - Revenue Recognition"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BasicAndDilutedEarningsPerCommonShare" xlink:title="00000023 - Disclosure - Basic and Diluted Earnings Per Common Share"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ShareholdersEquity" xlink:title="00000024 - Disclosure - Shareholders&apos; Equity"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTaxes" xlink:title="00000025 - Disclosure - Income Taxes"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Debt" xlink:title="00000026 - Disclosure - Debt"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Long-termDebt" xlink:title="00000027 - Disclosure - Long-term Debt"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Leases" xlink:title="00000028 - Disclosure - Leases"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/CommitmentsAndContingencies" xlink:title="00000029 - Disclosure - Commitments and Contingencies"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/DispositionOfSiteEquipmentToBeInstalledAndFixedAssets" xlink:title="00000030 - Disclosure - Disposition of Site Equipment to Be Installed and Fixed Assets"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SoftwareDevelopmentCosts" xlink:title="00000031 - Disclosure - Software Development Costs"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Goodwill" xlink:title="00000032 - Disclosure - Goodwill"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccumulatedOtherComprehensiveIncome" xlink:title="00000033 - Disclosure - Accumulated Other Comprehensive Income"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RecentAccountingPronouncements" xlink:title="00000034 - Disclosure - Recent Accounting Pronouncements"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RetirementSavingsPlan" xlink:title="00000035 - Disclosure - Retirement Savings Plan"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SubsequentEvents" xlink:title="00000036 - Disclosure - Subsequent Events"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/OrganizationAndDescriptionOfBusinessOperationsBrooklynImmunotherapeuticsLlc" xlink:title="00000037 - Disclosure - Organization and Description of Business Operations (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/DescriptionOfBusinessBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000038 - Disclosure - Description of Business (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoingConcernBrooklynImmunotherapeuticsLlc" xlink:title="00000039 - Disclosure - Going Concern (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc" xlink:title="00000040 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000041 - Disclosure - Summary of Significant Accounting Policies (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/FairValueOfFinancialInstrumentsBrooklynImmunotherapeuticsLlc" xlink:title="00000042 - Disclosure - Fair Value of Financial Instruments (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BusinessCombinationBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000043 - Disclosure - Business Combination (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/PropertyAndEquipmentBrooklynImmunotherapeuticsLlc" xlink:title="00000044 - Disclosure - Property and Equipment (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoodwillAndInProcessResearchAndDevelopmentBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000045 - Disclosure - Goodwill and in Process Research and Development (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SecurityDepositsAndOtherAssetsBrooklynImmunotherapeuticsLlc" xlink:title="00000046 - Disclosure - Security Deposits and Other Assets (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccruedExpensesBrooklynImmunotherapeuticsLlc" xlink:title="00000047 - Disclosure - Accrued Expenses (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/InvestorDepositsBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000048 - Disclosure - Investor Deposits (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/LoansPayableBrooklynImmunotherapeuticsLlc" xlink:title="00000049 - Disclosure - Loans Payable (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/LoansPayableAndLoansPayableToRelatedPartiesBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000050 - Disclosure - Loans Payable and Loans Payable to Related Parties (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/CommitmentsAndContingenciesBrooklynImmunotherapeuticsLlc" xlink:title="00000051 - Disclosure - Commitments and Contingencies (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Stock-basedCompensationBrooklynImmunotherapeuticsLlc" xlink:title="00000052 - Disclosure - Stock-Based Compensation (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/MembersEquityBrooklynImmunotherapeuticsLlc" xlink:title="00000053 - Disclosure - Members&apos; Equity (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquityBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000054 - Disclosure - Stockholders&apos; Deficiency and Members&apos; Equity (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTaxBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000055 - Disclosure - Income Tax (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SubsequentEventsBrooklynImmunotherapeuticsLlc" xlink:title="00000056 - Disclosure - Subsequent Events (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000057 - Disclosure - Summary of Significant Accounting Policies And Estimates (Policies)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc" xlink:title="00000058 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000059 - Disclosure - Summary of Significant Accounting Policies (Policies) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:title="00000060 - Disclosure - Summary of Significant Accounting Policies And Estimates (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/FixedAssetsNetTables" xlink:title="00000061 - Disclosure - Fixed Assets, Net (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccruedCompensationTables" xlink:title="00000062 - Disclosure - Accrued Compensation (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RevenueRecognitionTables" xlink:title="00000063 - Disclosure - Revenue Recognition (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ShareholdersEquityTables" xlink:title="00000064 - Disclosure - Shareholders&apos; Equity (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTaxesTables" xlink:title="00000065 - Disclosure - Income Taxes (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/LeasesTables" xlink:title="00000066 - Disclosure - Leases (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoodwillTables" xlink:title="00000067 - Disclosure - Goodwill (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BusinessCombinationTablesBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000068 - Disclosure - Business Combination (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/FairValueOfFinancialInstrumentsTablesBrooklynImmunotherapeuticsLlc" xlink:title="00000069 - Disclosure - Fair Value of Financial Instruments (Tables) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/PropertyAndEquipmentTablesBrooklynImmunotherapeuticsLlc" xlink:title="00000070 - Disclosure - Property and Equipment (Tables) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccruedExpensesTablesBrooklynImmunotherapeuticsLlc" xlink:title="00000071 - Disclosure - Accrued Expenses (Tables) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/CommitmentsAndContingenciesTablesBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000072 - Disclosure - Commitments and Contingencies (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquityTablesBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000073 - Disclosure - Stockholders&apos; Deficiency and Members&apos; Equity (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTaxTablesBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000074 - Disclosure - Income Tax (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000075 - Disclosure - Basis of Presentation (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/OrganizationOfCompanyDetailsNarrative10-k" xlink:title="00000076 - Disclosure - Organization of Company (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Covid-19UpdateDetailsNarrative" xlink:title="00000077 - Disclosure - Covid-19 Update (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoingConcernUncertaintyDetailsNarrative" xlink:title="00000078 - Disclosure - Going Concern Uncertainty (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoingConcernUncertaintyDetailsNarrative10-k" xlink:title="00000079 - Disclosure - Going Concern Uncertainty (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative10-k" xlink:title="00000080 - Disclosure - Summary of Significant Accounting Policies and Estimates (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfDisaggregationOfRevenuesDetails10-k" xlink:title="00000081 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Disaggregation of Revenues (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfRevenuesGeographicBreakdownDetails10-k" xlink:title="00000082 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Revenues Geographic Breakdown (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfContractLiabilitiesDetails10-k" xlink:title="00000083 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Contract Liabilities (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails10-k" xlink:title="00000084 - Disclosure - Summary of Significant Accounting Policies and Estimates - Schedule of Unamortized Installation Cost and Sales Commissions (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RestrictedCashDetailsNarrative" xlink:title="00000085 - Disclosure - Restricted Cash (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RestrictedCashDetailsNarrative10-k" xlink:title="00000086 - Disclosure - Restricted Cash (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/FixedAssetsNetDetailsNarrative10-k" xlink:title="00000087 - Disclosure - Fixed Assets, Net (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/FixedAssetsNet-ScheduleOfPropertyAndEquipmentDetails10-k" xlink:title="00000088 - Disclosure - Fixed Assets, Net - Schedule of Property and Equipment (Details) (10-K)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/FixedAssetsNet-ScheduleOfAssetGeographicBreakdownDetails10-k" xlink:title="00000089 - Disclosure - Fixed Assets, Net - Schedule of Asset Geographic Breakdown (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccruedCompensation-ScheduleOfAccruedCompensationDetails10-k" xlink:title="00000090 - Disclosure - Accrued Compensation - Schedule of Accrued Compensation (Details) (10-K)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedVacationCurrentAndNoncurrent"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccruedVacationCurrentAndNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedSalariesCurrentAndNoncurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccruedSalariesCurrentAndNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedBonusesCurrentAndNoncurrent"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccruedBonusesCurrentAndNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:label="loc_us-gaapAccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ConcentrationsOfRiskDetailsNarrative10-k" xlink:title="00000091 - Disclosure - Concentrations of Risk (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RevenueRecognition-DetailsNarrative" xlink:title="00000092 - Disclosure - Revenue Recognition - (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RevenueRecognition-ScheduleOfDisaggregatesMaterialRevenueDetails" xlink:title="00000093 - Disclosure - Revenue Recognition - Schedule of Disaggregates Material Revenue (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RevenueRecognition-ScheduleOfRevenuesGeographicBreakdownDetails" xlink:title="00000094 - Disclosure - Revenue Recognition - Schedule of Revenues Geographic Breakdown (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RevenueRecognition-ScheduleOfContractLiabilitiesDetails" xlink:title="00000095 - Disclosure - Revenue Recognition - Schedule of Contract Liabilities (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RevenueRecognition-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails" xlink:title="00000096 - Disclosure - Revenue Recognition - Schedule of Unamortized Installation Cost and Sales Commissions (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BasicAndDilutedEarningsPerCommonShareDetailsNarrative" xlink:title="00000097 - Disclosure - Basic and Diluted Earnings Per Common Share (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BasicAndDilutedEarningsPerCommonShareDetailsNarrative10-k" xlink:title="00000098 - Disclosure - Basic and Diluted Earnings Per Common Share (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000099 - Disclosure - Shareholders&apos; Equity (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ShareholdersEquityDetailsNarrative10-k" xlink:title="00000100 - Disclosure - Shareholders&apos; Equity (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ShareholdersEquity-ScheduleOfRestrictedStockAndCommonStockUnitVestedDetails" xlink:title="00000101 - Disclosure - Shareholders&apos; Equity - Schedule of Restricted Stock and Common Stock Unit Vested (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ShareholdersEquity-ScheduleOfWeightedAverageAssumptionsDetails10-k" xlink:title="00000102 - Disclosure - Shareholders&apos; Equity - Schedule of Weighted Average Assumptions (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ShareholdersEquity-SummaryOfStockOptionActivityDetails10-k" xlink:title="00000103 - Disclosure - Shareholders&apos; Equity - Summary of Stock Option Activity (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ShareholdersEquity-SummaryOfRestrictedStockUnitActivityDetails10-k" xlink:title="00000104 - Disclosure - Shareholders&apos; Equity - Summary of Restricted Stock Unit Activity (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/ShareholdersEquity-SummaryOfWarrantActivitiesDetails10-k" xlink:title="00000105 - Disclosure - Shareholders&apos; Equity - Summary of Warrant Activities (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTaxesDetailsNarrative10-k" xlink:title="00000106 - Disclosure - Income Taxes (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTaxes-ScheduleOfCurrentAndDeferredIncomeTaxProvisionBenefitDetails10-k" xlink:title="00000107 - Disclosure - Income Taxes - Schedule of Current and Deferred Income Tax Provision (Benefit) (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:title="00000108 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_NTNDeferredTaxAssetsLeaseLiabilities"/>
<link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_NTNDeferredTaxAssetsLeaseLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_DeferredTaxLiabilitiesDeferredExpenseForeign" xlink:label="loc_NTNDeferredTaxLiabilitiesDeferredExpenseForeign"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_NTNDeferredTaxLiabilitiesDeferredExpenseForeign" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_NTNDeferredTaxLiabilitiesRightOfUseAssets"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_NTNDeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTaxes-ScheduleOfReconciliationOfExpectedIncomeTaxesDetails10-k" xlink:title="00000109 - Disclosure - Income Taxes - Schedule of Reconciliation of Expected Income Taxes (Details) (10-K)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationDeductionsOther" xlink:label="loc_us-gaapIncomeTaxReconciliationDeductionsOther"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationDeductionsOther" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_IncomeTaxReconciliationPermanentItems" xlink:label="loc_NTNIncomeTaxReconciliationPermanentItems"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_NTNIncomeTaxReconciliationPermanentItems" xlink:type="arc" weight="-1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/DebtDetailsNarrative" xlink:title="00000110 - Disclosure - Debt (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Long-termDebtDetailsNarrative10-k" xlink:title="00000111 - Disclosure - Long-term Debt (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/LeasesDetailsNarrative" xlink:title="00000112 - Disclosure - Leases (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/LeasesDetailsNarrative10-k" xlink:title="00000113 - Disclosure - Leases (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:title="00000114 - Disclosure - Leases - Schedule of Operating Lease Right-of-use Assets and Liabilities (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:title="00000115 - Disclosure - Leases - Schedule of Operating Lease Right-of-use Assets and Liabilities (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfOperatingLeasesDetails" xlink:title="00000116 - Disclosure - Leases - Schedule of Maturities of Operating Leases (Details)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfOperatingLeasesDetails10-k" xlink:title="00000117 - Disclosure - Leases - Schedule of Maturities of Operating Leases (Details) (10-K)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:title="00000118 - Disclosure - Leases - Schedule of Financing Lease Right-of-use Assets and Liabilities (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:title="00000119 - Disclosure - Leases - Schedule of Financing Lease Right-of-use Assets and Liabilities (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails" xlink:title="00000120 - Disclosure - Leases - Schedule of Maturities of Financing Leases (Details)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails10-k" xlink:title="00000121 - Disclosure - Leases - Schedule of Maturities of Financing Leases (Details) (10-K)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/DispositionOfSiteEquipmentToBeInstalledAndFixedAssetsDetailsNarrative" xlink:title="00000122 - Disclosure - Disposition of Site Equipment to Be Installed and Fixed Assets (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SoftwareDevelopmentCostsDetailsNarrative" xlink:title="00000123 - Disclosure - Software Development Costs (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoodwillDetailsNarrative" xlink:title="00000124 - Disclosure - Goodwill (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoodwillDetailsNarrative10-k" xlink:title="00000125 - Disclosure - Goodwill (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Goodwill-ScheduleOfGoodwillDetails" xlink:title="00000126 - Disclosure - Goodwill - Schedule of Goodwill (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Goodwill-ScheduleOfGoodwillDetails10-k" xlink:title="00000127 - Disclosure - Goodwill - Schedule of Goodwill (Details) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccumulatedOtherComprehensiveIncomeDetailsNarrative" xlink:title="00000128 - Disclosure - Accumulated Other Comprehensive Income (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccumulatedOtherComprehensiveIncomeDetailsNarrative10-k" xlink:title="00000129 - Disclosure - Accumulated Other Comprehensive Income (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/RetirementSavingsPlanDetailsNarrative10-k" xlink:title="00000130 - Disclosure - Retirement Savings Plan (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SubsequentEventsDetailsNarrative10-k" xlink:title="00000131 - Disclosure - Subsequent Events (Details Narrative) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:title="00000132 - Disclosure - Going Conern (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:title="00000133 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/FairValueOfFinancialInstruments-ScheduleOfFairValueOfLiabilitiesDetailsBrooklynImmunotherapeuticsLlc" xlink:title="00000134 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value of Liabilities (Details) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/PropertyAndEquipmentDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:title="00000135 - Disclosure - Property and Equipment (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc" xlink:title="00000136 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:title="00000137 - Disclosure - Security Deposits and Other Assets (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc" xlink:title="00000138 - Disclosure - Accrued Expenses (Details) (Brooklyn ImmunoTherapeutics, LLC)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_NTNAccruedGeneralAndAdministrativeExpenses"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_NTNAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_NTNAccruedResearchAndDevelopmentExpenses"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_NTNAccruedResearchAndDevelopmentExpenses" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaapLitigationReserveCurrent"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapLitigationReserveCurrent" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/LoansPayableDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:title="00000139 - Disclosure - Loans Payable (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:title="00000140 - Disclosure - Commitments and Contingencies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/Stock-basedCompensationDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:title="00000141 - Disclosure - Stock-Based Compensation (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/MembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:title="00000142 - Disclosure - Members&apos; Equity (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SubsequentEventsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:title="00000143 - Disclosure - Subsequent Events (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000144 - Disclosure - Going Conern (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000145 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BusinessCombinationDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000146 - Disclosure - Business Combination (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/BusinessCombination-ScheduleOfPurchasePriceForAcquisitionDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000147 - Disclosure - Business Combination - Schedule of Purchase Price for Acquisition (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecurityDepositsAndOtherAssets" xlink:label="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecurityDepositsAndOtherAssets"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecurityDepositsAndOtherAssets" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLoansPayable" xlink:label="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLoansPayable"/>
<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLoansPayable" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLoansPayableRelatedParties" xlink:label="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLoansPayableRelatedParties"/>
<link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_NTNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLoansPayableRelatedParties" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/PropertyAndEquipmentDetailsNarativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000148 - Disclosure - Property and Equipment (Details Narative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000149 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/GoodwillAndInProcessResearchAndDevelopmentDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000150 - Disclosure - Goodwill and in Process Research and Development (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000151 - Disclosure - Security Deposits and Other Assets (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc10k" xlink:title="00000152 - Disclosure - Accrued Expenses (Details) (Brooklyn ImmunoTherapeutics, LLC) (10K)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_NTNAccruedGeneralAndAdministrativeExpenses"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_NTNAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_NTNAccruedResearchAndDevelopmentExpenses"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_NTNAccruedResearchAndDevelopmentExpenses" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaapLitigationReserveCurrent"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapLitigationReserveCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/InvestorDepositsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000153 - Disclosure - Investor Deposits (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/LoansPayableAndLoansPayableToRelatedPartiesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000154 - Disclosure - Loans Payable and Loans Payable to Related Parties (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000155 - Disclosure - Commitments and Contingencies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/CommitmentsAndContingencies-ScheduleOfFutureCommitmentsOfOperatingLeaseDetailsBrooklynImmunotherapeuticsLlc" xlink:title="00000156 - Disclosure - Commitments and Contingencies - Schedule of Future Commitments of Operating Lease (Details) (Brooklyn ImmunoTherapeutics, LLC)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000157 - Disclosure - Stockholders&apos; Deficiency and Members&apos; Equity (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionActivityDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000158 - Disclosure - Stockholders&apos; Deficiency and Members&apos; Equity - Schedule of Stock Option Activity (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionsOutstandingAndExercisableDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000159 - Disclosure - Stockholders&apos; Deficiency and Members&apos; Equity - Schedule of Stock Options Outstanding and Exercisable (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTaxDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000160 - Disclosure - Income Tax (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTax-ScheduleOfIncomeTaxBenefitDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000161 - Disclosure - Income Tax - Schedule of Income Tax Benefit (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K)">
<link:loc xlink:type="locator" xlink:href="ntn-20200630.xsd#NTN_FederalStateAndLocalCurrentAndDeferred" xlink:label="loc_NTNFederalStateAndLocalCurrentAndDeferred"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NTNFederalStateAndLocalCurrentAndDeferred" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NTNFederalStateAndLocalCurrentAndDeferred" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NTNFederalStateAndLocalCurrentAndDeferred" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NTNFederalStateAndLocalCurrentAndDeferred" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_NTNFederalStateAndLocalCurrentAndDeferred" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/IncomeTax-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000162 - Disclosure - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://buzztime.com/role/SubsequentEventsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:title="00000163 - Disclosure - Subsequent Events (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)"/>
</link:linkbase>

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/20/21  Eterna Therapeutics Inc.          S-4/A       1/19/21  182:20M                                    M2 Compliance LLC/FA
12/22/20  Eterna Therapeutics Inc.          S-4/A                183:20M                                    M2 Compliance LLC/FA
11/25/20  Eterna Therapeutics Inc.          S-4/A                207:22M                                    M2 Compliance LLC/FA

26 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/18/20  Eterna Therapeutics Inc.          8-K:1,2,5,7 9/18/20    9:777K                                   M2 Compliance LLC/FA
 8/14/20  Eterna Therapeutics Inc.          8-K:1,3,8,9 8/12/20    4:945K                                   M2 Compliance LLC/FA
 8/07/20  Eterna Therapeutics Inc.          10-Q        6/30/20   63:3.8M                                   M2 Compliance LLC/FA
 7/01/20  Eterna Therapeutics Inc.          8-K:1,9     6/25/20    2:64K                                    M2 Compliance LLC/FA
 6/02/20  Eterna Therapeutics Inc.          8-K:5,9     5/27/20    4:201K                                   M2 Compliance LLC/FA
 4/21/20  Eterna Therapeutics Inc.          8-K:1,2,8,9 4/18/20    3:1M                                     M2 Compliance LLC/FA
 3/30/20  Eterna Therapeutics Inc.          8-K:3,5,8,9 3/27/20    3:96K                                    M2 Compliance LLC/FA
 3/19/20  Eterna Therapeutics Inc.          10-K       12/31/19   84:5.7M                                   M2 Compliance LLC/FA
 3/17/20  Eterna Therapeutics Inc.          8-K:1,2,9   3/12/20    3:213K                                   M2 Compliance LLC/FA
 1/15/20  Eterna Therapeutics Inc.          8-K:1,5,7,9 1/13/20    5:654K                                   M2 Compliance LLC/FA
 9/17/19  Eterna Therapeutics Inc.          8-K:5,9     9/17/19    6:383K                                   M2 Compliance LLC/FA
 6/14/19  Eterna Therapeutics Inc.          S-8         6/14/19    8:531K                                   M2 Compliance LLC/FA
 4/26/19  Eterna Therapeutics Inc.          DEF 14A     4/26/19    1:999K                                   M2 Compliance LLC/FA
 3/22/19  Eterna Therapeutics Inc.          10-K       12/31/18   78:4.9M                                   M2 Compliance LLC/FA
 3/20/19  Eterna Therapeutics Inc.          8-K:2,5,9   3/19/19    3:381K                                   M2 Compliance LLC/FA
12/07/18  Eterna Therapeutics Inc.          8-K:5,8,9  12/06/18    3:186K                                   M2 Compliance LLC/FA
11/09/18  Eterna Therapeutics Inc.          10-Q        9/30/18   46:16M                                    M2 Compliance LLC/FA
10/01/18  Eterna Therapeutics Inc.          8-K:1,2,9   9/28/18    2:411K                                   M2 Compliance LLC/FA
 8/06/18  Eterna Therapeutics Inc.          10-Q        6/30/18   41:1.7M                                   M2 Compliance LLC/FA
 5/11/18  Eterna Therapeutics Inc.          10-Q        3/31/18   42:1.7M                                   M2 Compliance LLC/FA
 6/09/17  Eterna Therapeutics Inc.          8-K:5,9     6/08/17    2:65K                                    M2 Compliance LLC/FA
 4/12/17  Eterna Therapeutics Inc.          8-K:5,9     4/10/17    2:37K                                    M2 Compliance LLC/FA
 6/17/16  Eterna Therapeutics Inc.          8-K:5,8,9   6/16/16    3:1.1M                                   M2 Compliance LLC/FA
 4/24/15  Eterna Therapeutics Inc.          DEF 14A     6/05/15    1:963K                                   Publicease Inc./FA
11/07/14  Eterna Therapeutics Inc.          10-Q        9/30/14   56:2.1M                                   Publicease Inc./FA
 8/14/13  Brooklyn ImmunoTherapeutics, Inc. 10-Q        6/30/13   88:2.4M                                   Publicease Inc./FA
↑Top
Filing Submission 0001493152-20-018754   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Mon., May 13, 9:25:35.1am ET